Chemokines in tumor proximal fluids

Abstract

Chemokines are chemotactic cytokines produced by leukocytes and other types of cells including tumor cells. Their action is determined by the expression of cognate receptors and subsequent signaling in target cells, followed by the modulation of cytoskeletal proteins and the induction of other responses. In tumors, chemokines produced by neoplastic/stroma cells control the leukocyte infiltrate influencing tumor growth and progression. Tumor cells also express functional chemokine receptors responding to chemokine signals, promoting cell survival, proliferation and metastasis formation. Chemokines may be detected in serum of cancer patients, but due to the paracrine nature of these molecules, more significant concentrations are found in the tumor adjacent, non-vascular fluids, collectively called tumor proximal fluids. This review summarizes the expression of CC and CXC chemokines in these fluids, namely in interstitial fluid, pleural, ascitic, and cyst fluids, but also in urine, saliva, cerebrospinal fluid, cervical secretions and bronchoalveolar lavage fluid. Most comparative clinical studies reveal increased chemokine levels in high-grade tumor proximal fluids rather than in low-grade tumors and benign conditions, indicating shorter survival periods. The data confirm peritumoral fluid chemokines as sensitive diagnostic and prognostic markers, as well as offer support for chemokines and their receptors as potential targets for antitumor therapy.

Jawbone Cavitation Expressed RANTES/CCL5: Case Studies Linking Silent Inflammation in the Jawbone with Epistemology of Breast Cancer

“…As the metastatic properties of BC cells mediated by R/C are only transiently upregulated and the metastatic phenotype is reversible, 28 consequently, it could be challenging to detect the transient expression of molecules and phenotypes -like FDOJ-R/C overexpressionthat propagate BC. 25,60,65 As in essence, R/C is a potentially useful target for the prevention of BC cancer metastases 66,67 and as the metastatic phenotype might be reversible, 28 the author's surgical elimination of continuous FDOJ-R/C signaling input could be a therapeutic option to avoid metastatic outcomes. Individual genetic susceptibility provided a permanently increased expression of R/C in FDOJ sites that could exert inflammatory signaling in breast tissue.…”

<p><em>PF4V1</em>, an miRNA-875-3p target, suppresses cell proliferation, migration, and invasion in prostate cancer and serves as a potential prognostic biomarker</p>

“…Mounting evidence indicates that chemokines (chemotactic cytokines) play an important role in cancer microenvironment by binding cell surface receptors 15,16. Chemokines are divided into four families (C, CC, CX3C, and CXC) 17.…”

Collateral Damage Intended—Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy

“…Moreover, extrinsic mechanisms can contribute to resistance, demonstrating the important role that stromal cells play in the context of tumor neovascularization [ 258 ]. Tumor cells release many chemokines, inter alia the pro-angiogenic factors CCL2, CCL5, and CXCL12 [ 259 ] and cytokines, among them redundant pro-angiogenic cytokines, such as basic fibroblast growth factor (bFGF), interleukin-8 (IL-8), hepatocyte growth factor (HGF), PDGF, and VEGF [ 260 ], which are difficult to inhibit simultaneously. Furthermore, a tumor’s blood supply by non-angiogenically originated vessels ( Figure 3 ) is also not impaired by anti–angiogenic treatment [ 261 ].…”